DiaMedica Therapeutics, Inc.

  • Home
  • Our Focus
    • Overview
    • Literature & Publications
  • Pipeline
    • Overview
    • Preeclampsia & Fetal Growth Restriction
    • Acute Ischemic Stroke
  • Clinical Trials
    • Overview
    • Preeclampsia & Fetal Growth Restriction
    • Acute Ischemic Stroke
  • ReMEDy2 Trial
    • Overview
    • About ReMEDy2
    • Stroke Disease
    • For Physicians
    • Trial Locations
  • About DiaMedica
    • Overview
    • Leadership
    • Careers
    • Contact
  • Investors Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Data
    • Analyst Coverage
    • Financial Reports & SEC Filings
    • Governance
    • Resources

Events & Presentations

Investors Relations

Investors Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Data
    • Nasdaq Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • Financial Reports & SEC Filings
    • SEC Filings
    • Annual Reports
    • Tax Information (PFIC)
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • Investor Contact
    • FAQ
    • Share Consolidation Instructions
    • Email Alerts

DiaMedica Therapeutics Virtual KOL Event

May 28, 2025 8:00 am EST

DiaMedica Therapeutics Virtual KOL Event. Discussion on DM199 (Rinvecalinase Alfa) for the treatment of preeclampsia. Scheduled for Wednesday, May 28, 2025, at 8:00 AM ET. Includes a button labeled 'Click Here to Register & Attend'.

Click this link to listen to the replay

Click this link to view the presentation

Click here to read the call script

  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 DiaMedica Therapeutics, Inc. All Rights Reserved.
Twitter LinkedIn
Privacy Policy Disclaimer Sitemap